Rhytides Clinical Trial
Official title:
Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles
NCT number | NCT04994990 |
Other study ID # | 23-0015-NH |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | May 25, 2023 |
Est. completion date | May 30, 2025 |
Verified date | October 2023 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research is being done to determine if lower doses of botox than what is currently recommended can give similar results to patients, at lower cost and lower risk to them. Subjects will receive botox in the same areas of the upper face with standard doses on one side of the face. On the other side, double the botox concentration will be administered, free of charge to the participant, in order to see if the difference in concentration creates a difference in wrinkle reduction and participant satisfaction over time.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 30, 2025 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Provision of signed and dated informed consent form - Stated willingness to comply with all study procedures and availability for the duration of the study - Male or female, aged 18-65 - In good general health as evidenced by medical history and exhibiting upper facial wrinkles on physical examination - Agreement to adhere to Lifestyle Considerations (see section 5.3) as appropriate throughout study duration Exclusion Criteria: - Current use of aminoglycosides, curare like agents, and muscle relaxants - Pregnancy or lactation - Known allergic reactions to components of the botox formulation and any of its ingredients - Treatment with another botox product for the face within 4 months - Infections/preexisting weakness at the proposed injection sites on physical examination - History of neuromuscular disorder, pre existing severe cardiovascular disease, compromised respiratory function, severe dysphagia - Pediatric population, patients older than 65 since the effect of botox in terms of duration and magnitude is highly variable in these age groups. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Northwell Health |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Upper Face Wrinkle Severity 1 Week After Botox Administration | The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months. | 4 Months | |
Primary | Upper Face Wrinkle Severity 1 Month After Botox Administration | The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months. | 4 Months | |
Primary | Upper Face Wrinkle Severity 2 Months After Botox Administration | The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months. | 4 Months | |
Primary | Upper Face Wrinkle Severity 3 Months After Botox Administration | The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months. | 4 Months | |
Primary | Upper Face Wrinkle Severity 4 Months After Botox Administration | The severity of upper face wrinkles will be assessed on a 0 - 4 scale by a trained observer in both relaxed and expressive states. Efficacy will be assessed at 1 week, 1 month, 2 months, 3 months, and 4 months. | 4 Months | |
Primary | Patient Satisfaction 1 Week After Botox Administration | A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration | 4 Months | |
Primary | Patient Satisfaction 1 Month After Botox Administration | A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration | 4 Months | |
Primary | Patient Satisfaction 2 Months After Botox Administration | A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration | 4 Months | |
Primary | Patient Satisfaction 3 Months After Botox Administration | A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration | 4 Months | |
Primary | Patient Satisfaction 4 Months After Botox Administration | A satisfaction survey (on a scale of 0-10) will be administered to the participant at 1 week, 1 month, 2 months, 3 months and 4 months from the date of botox administration | 4 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00495443 -
Enhanced Safety Aesthetic Laser System
|
N/A | |
Completed |
NCT04586816 -
Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging
|
N/A | |
Completed |
NCT02954315 -
The Effect of Almonds on Skin Lipids and Wrinkles
|
N/A | |
Completed |
NCT01460927 -
TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides
|
N/A | |
Completed |
NCT01859611 -
TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides
|
N/A | |
Completed |
NCT05807412 -
Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides
|
Early Phase 1 | |
Completed |
NCT03776461 -
Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles
|
N/A | |
Completed |
NCT05514834 -
BCT-HA Kit for Dehydrated and Wrinkled Skin
|
Early Phase 1 | |
Enrolling by invitation |
NCT06104514 -
Safety and Efficacy of SofWave Treatment to Lift the Upper Lip and Improve the Peri-Oral Rhytids
|
N/A | |
Completed |
NCT03286283 -
The Use of J-Plasma® for Dermal Resurfacing
|
N/A | |
Completed |
NCT05041465 -
The Cosmetic Effect of Mineral Clay Masks
|
N/A | |
Completed |
NCT06421207 -
Open Label Study Exploring Tissue Histopathology After Ellacor® Procedure in an Abdominoplasty Model.
|
N/A | |
Completed |
NCT04185909 -
Renuvion Dermal System for Dermal Resurfacing
|
N/A | |
Completed |
NCT03831477 -
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles
|
N/A | |
Completed |
NCT05517538 -
Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique
|
N/A | |
Active, not recruiting |
NCT04162496 -
Restylane Refyne for Correction of Horizontal Neck Rhytides
|
N/A | |
Withdrawn |
NCT02659124 -
Comparison of AmnioFix Laser and Standard of Care Treatment
|
N/A |